Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

(2020) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

(2020) Qiuji Wu et al.   Frontiers in Oncology

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma

(2019) XiaoMin Wan et al.   JAMA Oncology

Breast cancer statistics, 2019

(2019) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

(2018) Amanda E. D. Van Swearingen et al.   BREAST CANCER RESEARCH AND TREATMENT

Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work

(2018) Gerard Harty et al.   Applied Health Economics and Health Policy

The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review

(2018) Gerard T. Vondeling et al.   Applied Health Economics and Health Policy

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

(2018) Bin Wu et al.   ONCOLOGIST

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy

(2018) Aman U. Buzdar et al.   JAMA Oncology

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

US drug prices should be tied to foreign prices to tackle “global freeloading,” says Trump

(2018) Owen Dyer   BMJ-British Medical Journal

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer

(2016) Quang A. Le et al.   BREAST CANCER RESEARCH AND TREATMENT

Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

(2016) Vakaramoko Diaby et al.   BREAST CANCER RESEARCH AND TREATMENT

Toward Value-Based Pricing to Boost Cancer Research and Innovation

(2016) A. Ocana et al.   CANCER RESEARCH

A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada

(2016) C. Beauchemin et al.   JOURNAL OF MEDICAL ECONOMICS

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

(2015) Karen A. Gelmon et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer

(2011) Peter S. Hall et al.   PHARMACOECONOMICS

Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer

(2009) Quang A. Le et al.   CANCER